首页> 美国卫生研究院文献>Journal of Clinical Medicine >Pregabalin Failed to Prevent Dry Eye Symptoms after Laser-Assisted in Situ Keratomileusis (LASIK) in a Randomized Pilot Study
【2h】

Pregabalin Failed to Prevent Dry Eye Symptoms after Laser-Assisted in Situ Keratomileusis (LASIK) in a Randomized Pilot Study

机译:普瑞巴林在预防激光辅助原位角膜磨镶术(LASIK)后未能预防干眼症

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Purpose: Perioperative pregabalin administration has been found to reduce the risk of persistent pain after a variety of surgical procedures. However, this approach has not been tested in relation to eye surgery. As such, the purpose of this study was to evaluate whether perioperative pregabalin can reduce the presence of dry eye (DE) symptoms, including eye pain, six months after laser-assisted in situ keratomileusis (LASIK). Methods: Prospective, masked, randomized single-center pilot study. Patients were treated with either pregabalin (oral solution of pregabalin 150 mg twice daily, first dose prior to surgery, continued for a total of 28 doses over 14 days) or placebo solution. The primary outcome was dry eye symptoms as measured by the Dry Eye Questionnaire 5 (DEQ-5). Secondary outcome measures included pain-related eye symptoms. Results: In total, 43 individuals were enrolled in the study and randomized to pregabalin (n = 21) or placebo (n = 22). Of those, 42 individuals completed the final visit after six months of follow-up. Some differences were noted between the two groups at baseline, including a higher frequency of females in the pregabalin group. At 6-months, there were no significant differences in the percentage of patients with DE symptoms (DEQ5 ≥ 6, 57% vs. 33%, p = 0.14), DE symptom severity (DEQ5, 6.6 ± 5.0 vs. 4.5 ± 4.2, p = 0.14), ocular pain intensity (numerical rating scale, 1.10 ± 1.48 vs. 0.38 ± 0.97, p = 0.08), or neuropathic pain complaints (Neuropathic Pain Symptom Inventory-Eye, 2.81 ± 4.07 vs. 3.14 ± 5.85, p = 0.83) between the pregabalin and control groups. Ocular signs were likewise similar between the groups, and of note, did not correlate with DE symptoms. The strongest predictor of DE symptoms six months post-surgery was the presence of DE symptoms prior to surgery. Conclusions: Perioperative pregabalin did not reduce the frequency or severity of DE symptoms at a six month follow-up after LASIK in this small pilot study.
机译:目的:已发现围手术前服用普瑞巴林可减少各种外科手术后持续疼痛的风险。但是,这种方法尚未经过与眼科手术有关的测试。因此,本研究的目的是评估围手术期普瑞巴林能否减轻激光辅助原位角膜磨镶术(LASIK)六个月后出现的干眼症(DE)症状,包括眼痛。方法:前瞻性,隐蔽,随机的单中心试验研究。患者接受普瑞巴林(普瑞巴林150 mg口服溶液,每天两次,手术前第一剂,在14天之内共28剂)或安慰剂溶液治疗。主要结果是根据干眼问卷5(DEQ-5)测得的干眼症状。次要结果指标包括与疼痛有关的眼部症状。结果:总共有43个人被纳入研究,并随机分配给普瑞巴林(n = 21)或安慰剂(n = 22)。其中有42个人在六个月的随访后完成了最终访问。基线时两组之间存在一些差异,包括普瑞巴林组中女性的频率更高。在6个月时,有DE症状(DEQ5≥6,57%比33%,p = 0.14),DE症状严重程度(DEQ5,6.6±5.0 vs. 4.5±4.2, p = 0.14),眼痛强度(数字评分量表,1.10±1.48和0.38±0.97,p = 0.08)或神经性疼痛症状(神经性疼痛症状量表-眼,2.81±4.07 vs.3.14±5.85,p = 0.83)在普瑞巴林和对照组之间。两组之间的眼征同样相似,并且值得注意的是,与DE症状无关。术后六个月DE症状的最强预测因子是手术前是否存在DE症状。结论:在这项小规模的前瞻性研究中,围手术期普瑞巴林在LASIK术后六个月随访中并未降低DE症状的发生频率或严重程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号